최희경 (한양대학교) | 한빛사논문 > 한빛사

한빛사논문

조회483

최희경Heekyung Choi

한양대학교

Adv. Mater., Jan 11 2024, | https://doi.org/10.1002/adma.202309920 Self-Assembled Oligopeptoplex-Loaded Dissolving Microneedles for Adipocyte-Targeted Anti-Obesity Gene Therapy

Heekyung Choi^1,2, Juhyeong Hong ^1,2, Yuha Seo ^1,2, Seung-Hwan Joo ^1,2, Hanseok Lim ^1,2, Shayan Fakhraei Lahiji ^1,3, Yong-Hee Kim ^1,2,3

¹Department of Bioengineering, Institute for Bioengineering and Biopharmaceutical Research, Hanyang University, Seoul, 04763, Republic of Korea.

²Education and Research Group for Biopharmaceutical Innovation Leader, Hanyang University, Seoul, 04763, Republic of Korea.

³Cursus Bio Inc., Icure Tower, Seoul, 06170, Republic of Korea.

H.C. and J.H. contributed equally to this work.

CORRESPONDING AUTHORS : Shayan Fakhraei Lahiji, Yong-Hee Kim

Abstract

Advancements in gene delivery systems are pivotal for gene-based therapeutics in oncological, inflammatory, and infectious diseases. This study delineates the design of a self-assembled oligopeptoplex (SA-OP) optimized for shRNA delivery to adipocytes, targeting obesity and associated metabolic syndromes. Conventional systems face challenges, including instability due to electrostatic interactions between genetic materials and cationic oligopeptides. Additionally, repeated injections induce discomfort and compromise patient well-being. To circumvent these issues, a dissolvable hyaluronic acid-based, self-locking microneedle (LMN) patch is developed, with improved micro-dose efficiency, for precise SA-OP delivery. This platform offers pain-free administration and improved SA-OP storage stability. In vitro studies in 3T3-L1 cells demonstrated improvements in SA-OP preservation and gene silencing efficacy. In vivo evaluation in a mice model of diet-induced type 2 diabetes yielded significant gene silencing in adipose tissue and a 21.92 ± 2.51% reduction in body weight with minimum relapse risk at 6-weeks post-treatment, representing a superior therapeutic efficacy in a truncated timeframe relative to the GLP-1 analogues currently available on the market. Additionally, SA-OP (LMN) mitigated insulin resistance, inflammation, and hepatic steatosis. These findings establish SA-OP (LMN) as a robust, minimally invasive transdermal gene delivery platform with prolonged storage stability for treating obesity and its metabolic comorbidities.

논문정보

형식Research article
게재일2024년 01월 (BRIC 등록일 2024-01-15)
연구진국내 연구진
분야 바이오·의료융합 > 바이오·의료융합 기타

댓글 작성 로그인

CV 열람하기

연락처 보기